Gradient Investments LLC lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 443,592 shares of the medical equipment provider’s stock after selling 24,743 shares during the quarter. Gradient Investments LLC’s holdings in Boston Scientific were worth $19,363,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $2,156,233,000. Jupiter Topco LLC acquired a new position in Boston Scientific during the second quarter worth approximately $803,357,000. Bank of America Corp DE bought a new stake in Boston Scientific in the 2nd quarter valued at $556,026,000. Finally, Legal & General Group Plc bought a new position in shares of Boston Scientific in the second quarter valued at about $431,890,000. Institutional investors own 89.07% of the company’s stock.
Insider Activity at Boston Scientific
In other news, Director David Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward Ludwig purchased 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 194,522 shares of company stock valued at $9,385,210 in the last three months. Corporate insiders own 0.34% of the company’s stock.
More Boston Scientific News
- Positive Sentiment: Boston Scientific appointed longtime cardiovascular executive Joseph M. Fitzgerald as executive vice president and chief operating officer and reorganized its operations into three segments. Management said the structure is intended to improve efficiency and support continued growth, which could strengthen execution over time. Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Neutral Sentiment: Barclays initiated coverage of Boston Scientific with an “equal weight” rating, later described as “hold.” The stance suggests the firm sees a balanced risk-reward profile rather than a clear catalyst for significant near-term appreciation. Barclays initiates coverage of Boston Scientific with equal-weight
- Neutral Sentiment: Boston Scientific is attracting increased attention from Zacks users, but the report does not identify a new earnings surprise or material fundamental change. The company’s latest reported quarter exceeded consensus estimates, although current trading is being driven more by sentiment and analyst commentary. Boston Scientific Corporation is Attracting Investor Attention
- Negative Sentiment: Shares fell to a new one-year low near $41.50, signaling continued technical weakness. The stock is trading well below its 50-day and 200-day moving averages, which can encourage additional selling and reflects investor concern despite the company’s longer-term growth prospects. Boston Scientific Reaches New 1-Year Low
- Negative Sentiment: Citigroup issued a pessimistic forecast for BSX, adding to the negative analyst tone surrounding the stock. The bearish outlook, combined with the new low and Barclays’ lack of a buy rating, is likely weighing on investor confidence. Citigroup Issues Pessimistic Forecast for Boston Scientific
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on BSX. Evercore set a $65.00 target price on Boston Scientific in a report on Monday, July 6th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. UBS Group decreased their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Oppenheimer lowered their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a report on Monday, September 21st. Finally, Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $66.31.
Check Out Our Latest Stock Report on Boston Scientific
Boston Scientific Trading Up 0.2%
BSX traded up $0.08 during trading on Thursday, hitting $41.66. The company’s stock had a trading volume of 7,215,731 shares, compared to its average volume of 18,643,260. Boston Scientific Corporation has a twelve month low of $41.44 and a twelve month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock’s fifty day moving average price is $46.72 and its 200-day moving average price is $50.90. The firm has a market capitalization of $60.37 billion, a P/E ratio of 16.90, a PEG ratio of 1.01 and a beta of 0.58.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.25 EPS for the current year.
Boston Scientific Profile
Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.
The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.
Read More
- Five stocks we like better than Boston Scientific
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
